Halozyme Therapeutics (HALO) PT Lowered to $62 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Do Kim lowered the price target on Halozyme Therapeutics (NASDAQ: HALO) to $62.00 (from $66.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
